PMID- 36516040
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20230418
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 38
IP  - 4
DP  - 2023 Apr
TI  - Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for 
      advanced hepatocellular carcinoma: A systematic review and meta-analysis.
PG  - 486-495
LID - 10.1111/jgh.16088 [doi]
AB  - BACKGROUND: The combination of sorafenib and hepatic arterial infusion 
      chemotherapy (HAIC) is expected to exert a synergistic anticancer effect. We 
      conducted this systematic review to examine the efficacy and safety of sorafenib 
      plus HAIC vs sorafenib alone for advanced hepatocellular carcinoma (HCC). 
      METHODS: We systematically searched the PubMed, Embase, and Cochrane Library with 
      the following search terms: "sorafenib," "hepatic arterial infusion 
      chemotherapy," "HAIC," "advanced," "hepatocellular carcinoma," and "HCC." Pooled 
      hazard ratios (HRs) and 95% CIs were calculated for overall survival (OS) and 
      progression-free survival (PFS), and we calculated the pooled risk ratios (RRs) 
      and 95% CIs for objective response rate (ORR) and adverse events (AEs). RESULTS: 
      We found that sorafenib plus HAIC was associated with significantly better OS 
      (HR, 0.56; 95% CI, 0.37-0.83; P < 0.01), PFS (HR, 0.44; 95% CI, 0.27-0.72; 
      P < 0.01), and ORR (RR, 3.77; 95% CI, 1.87-7.58; P < 0.01) than sorafenib alone 
      in advanced HCC. Grade 3/4 AEs were more frequent in the sorafenib plus HAIC 
      group, including leukopenia (RR, 4.54; 95% CI, 1.77-11.64; P < 0.01), neutropenia 
      (RR, 7.81; 95% CI, 3.36-18.16; P < 0.01), thrombocytopenia (RR, 2.97; 95% CI, 
      1.98-4.46; P < 0.01), anemia (RR, 2.24; 95% CI, 1.22-4.09; P < 0.01), anorexia 
      (RR, 2.37; 95% CI, 1.07-5.27; P = 0.03), nausea (RR, 2.98; 95% CI, 1.19-7.42; 
      P = 0.02), and vomiting (RR, 3.99; 95% CI, 1.14-14.01; P = 0.03). CONCLUSION: 
      Sorafenib plus HAIC improved OS, PFS, and ORR compared with sorafenib alone in 
      advanced HCC, with acceptable safety profile.
CI  - (c) 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Long, Yin
AU  - Long Y
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Song, Xingdong
AU  - Song X
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Guan, Yan
AU  - Guan Y
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Lan, Ran
AU  - Lan R
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Huang, Ziqi
AU  - Huang Z
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Li, Senlin
AU  - Li S
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen 
      Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Zhang, Lei
AU  - Zhang L
AUID- ORCID: 0000-0002-9301-0181
AD  - Department of Hepatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
GR  - 2017A030313871/Natural Science Foundation of Guangdong Province/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230116
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular
MH  - Sorafenib/therapeutic use
MH  - *Liver Neoplasms/pathology
MH  - Treatment Outcome
MH  - Infusions, Intra-Arterial
MH  - *Thrombocytopenia/etiology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - combination therapy
OT  - hepatic arterial infusion chemotherapy
OT  - hepatocellular carcinoma
OT  - sorafenib
EDAT- 2022/12/15 06:00
MHDA- 2023/04/18 06:42
CRDT- 2022/12/14 12:33
PHST- 2022/11/12 00:00 [revised]
PHST- 2022/08/30 00:00 [received]
PHST- 2022/12/10 00:00 [accepted]
PHST- 2023/04/18 06:42 [medline]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/14 12:33 [entrez]
AID - 10.1111/jgh.16088 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2023 Apr;38(4):486-495. doi: 10.1111/jgh.16088. Epub 
      2023 Jan 16.